Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DNMT1 | P26358 | 3/20 | 0.66 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.66 |
| ▸ | POLB | P06746 | 1/20 | 0.62 |
| ▸ | LMNA | P02545 | 5/20 | 0.62 |
| ▸ | THRB | P10828 | 1/20 | 0.62 |
| ▸ | MTOR | P42345 | 1/20 | 0.62 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.62 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.62 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.62 |
| ▸ | PDE3A | Q14432 | 4/20 | 0.59 |
| ▸ | CACNA1F | O60840 | 2/20 | 0.59 |
| ▸ | ALB | P02768 | 2/20 | 0.59 |
| ▸ | MAPT | P10636 | 2/20 | 0.59 |
| ▸ | CACNA1D | Q01668 | 2/20 | 0.59 |
| ▸ | CACNA1S | Q13698 | 2/20 | 0.59 |
| ▸ | CACNA1C | Q13936 | 2/20 | 0.59 |
| ▸ | PDE4D | Q08499 | 2/20 | 0.58 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.58 |
| ▸ | P2RY2 | P41231 | 3/20 | 0.51 |
| ▸ | P2RY4 | P51582 | 3/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Doxecitine SCHEMBL29910618 | 1.00 | DNMT1 (0.66) | DNMT1ADRB1POLBLMNATHRB | |
| Doxecitine SCHEMBL30616799 | 1.00 | DNMT1 (0.66) | DNMT1ADRB1POLBLMNATHRB | |
| Doxecitine SCHEMBL15832461 | 1.00 | DNMT1 (0.66) | DNMT1ADRB1POLBLMNATHRB | |
| Doxecitine SCHEMBL887491 | 1.00 | DNMT1 (0.66) | DNMT1ADRB1POLBLMNATHRB | |
| Doxecitine SCHEMBL31503186 | 1.00 | DNMT1 (0.66) | DNMT1ADRB1POLBLMNATHRB | |
| Doxecitine SCHEMBL23346798 | 1.00 | DNMT1 (0.66) | DNMT1ADRB1POLBLMNATHRB | |
| Doxecitine SCHEMBL13700553 | 1.00 | DNMT1 (0.66) | DNMT1ADRB1POLBLMNATHRB | |
| Doxecitine SCHEMBL23178 | 1.00 | DNMT1 (0.66) | DNMT1ADRB1POLBLMNATHRB | |
| Doxecitine SCHEMBL193815 | 1.00 | DNMT1 (0.66) | DNMT1ADRB1POLBLMNATHRB | |
| Doxecitine SCHEMBL2623809 | 1.00 | DNMT1 (0.66) | DNMT1ADRB1POLBLMNATHRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 106 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119235893-A | Application of 2' -deoxycytidine in preparation of medicine for treating atherosclerosis | 上海交通大学医学院附属瑞金医院 | 2025-01-03 | — | — | CN | claimed |
| US-20260097062-A1 | AQUEOUS SOLUTIONS CONTAINING PURINES AND PYRIMIDINES AND USES THEREOF | UCB BIOSCIENCES INC (US) | 2026-04-09 | — | — | US | disclosed |
| EP-4716745-A1 | NEW TLR-4 ANTAGONIST APTAMERS | Merck Patent GmbH (DE) | 2026-04-01 | — | — | EP | disclosed |
| EP-4704831-A2 | SUBSTITUTED PYRIMIDINONE AND AZAPYRIMIDINONE COMPOUNDS, COMPOSITIONS, AND USES THEREOF | Lakewood Amedex, Inc. (US) | 2026-03-11 | — | — | EP | disclosed |
| US-20260066042-A1 | METHODS AND SYSTEMS FOR HIGH-THROUGHPUT MOLECULAR ANALYSIS | OPENTRONS LABWORKS INC (US) | 2026-03-05 | — | — | US | disclosed |
| US-20250367301-A1 | PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING TRIPLE-NEGATIVE BREAST CANCER, COMPRISING OLIGONUCLEOTIDE AS ACTIVE INGREDIENT | INTEROLIGO CORPORATION (KR) | 2025-12-04 | — | — | US | disclosed |
| US-12465615-B2 | Aqueous solutions containing purines and pyrimidines and uses thereof | UCB BIOSCIENCES, INC. (US) | 2025-11-11 | — | — | US | disclosed |
| US-12460267-B2 | Compositions and methods for detection of Mycoplasma genitalium | ROCHE MOLECULAR SYSTEMS, INC. (US) | 2025-11-04 | — | — | US | disclosed |
| EP-4543898-A1 | PYRIMIDINE NUCLEOSIDE TREATMENTS | The Children's Medical Center Corporation (US) | 2025-04-30 | — | — | EP | disclosed |
| WO-2025037497-A1 | METHOD FOR PRODUCING SMALL INTESTINE TISSUE | 国立大学法人京都大学 | 2025-02-20 | — | — | WO | disclosed |
| US-20100203541-A1 | NUCLEOTIDE ANALOGS | HELICOS BIOSCIENCES CORPORATION (US) | 2010-08-12 | — | — | US | disclosed |
| US-7678894-B2 | Nucleotide analogs | HELICOS BIOSCIENCES CORPORATION (US) | 2010-03-16 | — | — | US | disclosed |
| US-7678894-B2 | Nucleotide analogs | HELICOS BIOSCIENCES CORPORATION (US) | 2010-03-16 | — | — | US | disclosed |
| EP-1383732-B1 | LABELLING REAGENTS, METHOD FOR SYNTHESIS OF SAID REAGENTS AND METHODS FOR DETECTING BIOLOGICAL MOLECULES | BIO MERIEUX (FR) | 2010-02-17 | — | — | EP | disclosed |
| US-7553809-B2 | Fc receptor modulators and uses thereof | ILEXUS PTY LIMITED (AU) | 2009-06-30 | — | — | US | disclosed |
| WO-2008144544-A1 | NUCLEOTIDE ANALOGS | HELICOS BIOSCIENCES CORPORATION (US) | 2008-11-27 | — | — | WO | disclosed |
| US-20080286837-A1 | Nucleotide analogs | HELICOS BIOSCIENCES CORPORATION (US) | 2008-11-20 | — | — | US | disclosed |
| US-20080286837-A1 | Nucleotide analogs | HELICOS BIOSCIENCES CORPORATION (US) | 2008-11-20 | — | — | US | disclosed |
| US-7338805-B2 | Labeling reagents, methods for synthesizing such reagents and methods for detecting biological molecules | BIO MERIEUX (FR) | 2008-03-04 | — | — | US | disclosed |
| US-7338805-B2 | Labeling reagents, methods for synthesizing such reagents and methods for detecting biological molecules | BIO MERIEUX (FR) | 2008-03-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260097062-A1 | AQUEOUS SOLUTIONS CONTAINING PURINES AND PYRIMIDINES AND USES THEREOF | POLG, POLRMT, TK2 | DNMT1 624/4885ADRB1 4556/4885POLB 4/4885 |
| US-20100203541-A1 | NUCLEOTIDE ANALOGS | NT5C2, NT5E, NUDT1 | DNMT1 171/4885ADRB1 4618/4885POLB 312/4885 |
| US-12465615-B2 | Aqueous solutions containing purines and pyrimidines and uses thereof | FPGS, NUDT1, POLRMT | DNMT1 2147/4885ADRB1 2684/4885POLB 183/4885 |
| US-20260066042-A1 | METHODS AND SYSTEMS FOR HIGH-THROUGHPUT MOLECULAR ANALYSIS | POLRMT, POLL, SARS1 | DNMT1 1090/4885ADRB1 2217/4885POLB 12/4885 |
| US-20250367301-A1 | PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING TRIPLE-NEGATIVE BREAST CANCER, COMPRISING OLIGONUCLEOTIDE AS ACTIVE INGREDIENT | BRCA1, POLN, POLRMT | DNMT1 1266/4885ADRB1 4607/4885POLB 5/4885 |
| US-20080286837-A1 | Nucleotide analogs | NT5C2, NT5E, NUDT1 | DNMT1 171/4885ADRB1 4618/4885POLB 312/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.